The American Neurological Association’s 150th Annual Meeting held in Baltimore last week was a milestone meeting celebrating 150 years of progress, discovery, advances in science, and the remarkable work of academic neurologists and neuroscientists over the past century and a half. The meeting—ANA2025—featured outstanding plenary sessions, professional development workshops, interactive lunch workshops, special interest groups, cross-cutting special interest groups, the celebrated poster hall, satellite symposia, and several opportunities to network and connect with colleagues and friends.

Dr. Michelle Johansen of Johns Hopkins University School of Medicine, immediate past chair of the ANA Education Innovation Committee, engaged with meeting attendees to learn more about their experience at ANA2025 and what they think about the ANA. Listen in as meeting attendees share their insights, meeting highlights, and enthusiasm for the ANA during Dr. Johansen’s boots on the ground interactions with them. From the Presidential Symposium to the closing sessions, learn about ANA2025, the science and research shared, and the reactions of those who were in Baltimore to experience it.

Tune into the latest podcast from the American Neurological Association (ANA), ANA Investigates: 75 Years of NINDS. This year marks the 75th anniversary of the National Institute of Neurological Disorders and Stroke (NINDS)—an opportunity to reflect on the institute’s past achievements and look ahead to the future of neurological research.

This month, ANA Investigates welcomes Dr. Walter Koroshetz, Director of NINDS, in conversation with Dr. Adeline Goss, Neurohospitalist at Highland Hospital. Dr. Koroshetz joined the institute in 2007 as Deputy Director and became Director in 2015. Before joining the NINDS, he served as Vice Chair of Neurology, Director of Stroke and Neurointensive Care Services at Massachusetts General Hospital, and neurologist in the MGH Huntington’s Disease Clinic.

Tune in as they discuss highlights from the NINDS’s 75-year history and explore what lies ahead for neurological research and innovation.

• Guest: Walter J. Koroshetz, MD, FANA Director National Institute of Neurological Disorders and Stroke
• Interviewer: Adeline Goss, MD Neurohospitalist Highland Hospital
• Disclosures: None

Today we’ll focus on a major shift in the treatment of myasthenia gravis -- as a wave of new therapies is changing how we treat this disease. Who should be considered for these new treatments? And what else is in the pipeline?

Our guest today is Dr.  Gil Wolfe, a neuromuscular neurologist at the University of Buffalo State University of New York, Jacob School of Medicine and Biomedical Sciences. Dr. Wolfe was interviewed by Dr. Ioannis Karakis, adjunct professor of neurology at Emory University School of Medicine.

References:

• https://www.nature.com/articles/s41598-024-79918-7

Disclosures: Dr. Wolfe discloses: Consultant for: Alexion, Argenx, BPL, Cartesian, Canopy, Grifols, Johnson & Johnson, Takeda, UCB; Speaker Bureau for: Grifols, Alexion, UCB; Grant/Research support from: ArgenX, Ra/UCB, Immunovant, Roche, Alexion, Sanofi

Climate change is no longer a distant worry—it’s showing up in neurology clinics across the US, from Lyme meningitis in the Midwest to worsening migraines during heat waves, climate-linked and vector-borne neurological conditions are entering the differential.

Our guests today are two experts on climate change and neurological health: Dr. Beth Malow, Professor of Neurology and Pediatrics at Vanderbilt University Medical Center, and Dr. Monica Diaz, Assistant Professor of Neurology at the University of North Carolina at Chapel Hill. They’ll explore the clinical impact of climate change on neurology, and how neurologists can adapt through patient care, advocacy, and research.

Drs. Malow and Diaz were interviewed by Dr. Sara Stern-Nezer, Associate Professor of Neurology at the University of California, Irvine.

• Interviewer: Dr. Sara Stern-Nezer, Associate Professor of Neurology at the University of California, Irvine
• Guests: Dr. Beth Ann Malow, Professor of Neurology and Pediatrics at Vanderbilt University Medical Center, and Dr. Monica Diaz, Assistant Professor of Neurology at the University of North Carolina at Chapel Hill
• Disclosure: Dr. Malow serves as a consultant for Neurim Pharmaceuticals.
• Resources: Neurologists Interested in Climate and Health (NICHE)
  • Climate Change and Brain Health: What Do We Know and What Can We Do? http://nichebrainhealth.com/what-we-can-do/

Restless leg syndrome is a common movement and sleep disorder affecting 2-3% of the population. Certain neurologic disorders are associated with a higher incidence, and neuropsychiatric medications prescribed by neurologists and psychiatrists often exacerbate these symptoms. In January, the American Academy of Sleep Medicine published updated guidelines for the evaluation and treatment of RLS. The recommendations shifted from recommending the use of dopamine agonists, to prioritizing iron evaluation and supplementation, alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin), and recommending against the long-term use of dopamine agonists. The guidelines also recommend opiates for moderate-severe medication refractory RLS. Dr. Winkleman is a Professor of Psychiatry at Harvard Medical School and chief of the Sleep Disorders Clinical Research Program in the Department of Psychiatry at Massachusetts General Hospital. He is the first-author on the new guidelines, and is here to discuss these changes and what is needed to effectively change practice. He is interviewed by Dr. Kara Wyant, Clinical Assistant Professor of Neurology, University of Michigan Medical School. RLS Curbside

Look around you right now and think for a minute about all of the things you’re exposed to: the coffee you’re drinking, the mug holding the coffee you’re drinking, the soap that mug was washed in, the sleep you got last night -- or didn’t get. All of this is part of what we now call your exposome. And as we’re learning, the neural exposome influences our risk of developing a range of neurologic diseases.

Our guest today is Dr. Eva Feldman, the  James W Albers Distinguished University Professor and the Russell N. De Young professor of neurology and neurosurgery at the University of Michigan. She’ll talk to us about research on the neural exposome in neurodegenerative disease -- and what we should be telling patients and policymakers about this research. Dr. Feldman was interviewed by Dr. Vinita Acharya, Professor of Neurology and Distinguished Educator at Penn State College of Medicine.

• Guest: Dr. Eva Feldman, the  James W Albers Distinguished University Professor and the Russell N. De Young professor of neurology and neurosurgery at the University of Michigan - https://medicine.umich.edu/dept/mni/eva-feldman-md-phd
• Interviewer: Dr. Vinita Acharya, Professor of Neurology and Distinguished Educator at Penn State College of Medicine
• Disclosures: None

Neurologists bring an important perspective to health policy. But few have formal training in how to advocate for patients at a state or national level. Our guest today, Dr. Kara Stavros, is an associate professor of neurology at The Warren Alpert Medical School of Brown University and the President of the Rhode Island Medical Society. She’s also a self-described advocate, who’s found a number of ways to speak up for her patients and influence health policy. Dr. Stavros spoke about her path to advocacy with Dr. Sarah Nelson, Assistant Professor of Neurology at Tufts Medical Center.

• Guest: Dr. Kara Stavros, associate professor of neurology at The Warren Alpert Medical School of Brown University and the President of the Rhode Island Medical Society
• Interviewer: Dr. Sarah Nelson, Assistant Professor of Neurology at Tufts Medical Center
• Disclosures: None

Parkinson’s Disease has long been a clinical diagnosis. But recently, there have been proposals to redefine the disease based on biomarkers of alpha-synucleinopathy and dopaminergic dysfunction. A similar shift has already occurred in Alzheimer disease, with the “amyloid, tau, and neurodegeneration,” or ATN, classification system.

Our guest today, Michael Okun, is is Professor of Neurology and Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida and medical advisor for the Parkinson's Foundation. He co-authored an op-ed in JAMA last summer in JAMA arguing that there would be benefits to a biological definition of Parkinson’s - but there would also be risks. He’ll unpack both sides of this debate today with Dr. Christine Doss Esper, Associate Professor of Neurology at Emory University. Series 6, Episode 5

Featuring:

• Guest: Dr. Michael Okun, is Professor of Neurology and Director of the Norman Fixel Institute for Neurological Diseases at the University of Florida and medical advisor for the Parkinson's Foundation
• Interviewer: Dr. Christine Doss Esper, Associate Professor of Neurology at Emory University
• Disclosures: None